A1 Refereed original research article in a scientific journal
Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation
Authors: Itainen-Stromberg S, Hekkala AM, Aro AL, Vasankari T, Airaksinen KEJ, Lehto M
Publisher: WILEY
Publication year: 2020
Journal: Annals of Noninvasive Electrocardiology
Journal name in source: ANNALS OF NONINVASIVE ELECTROCARDIOLOGY
Journal acronym: ANN NONINVAS ELECTRO
Article number: ARTN e12766
Volume: 25
Issue: 5
Number of pages: 7
ISSN: 1082-720X
DOI: https://doi.org/10.1111/anec.12766
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/47564024
Background Nonvitamin K antagonist oral anticoagulants (NOACs) are increasingly used in patients with atrial fibrillation (AF) undergoing elective cardioversion (ECV). The aim was to investigate the use of NOACs and warfarin in ECV in a real-life setting and to assess how the chosen regimen affected the delay to ECV and rate of complications.Methods Consecutive AF patients undergoing ECVs in the city hospitals of Helsinki between January 2015 and December 2016 were studied. Data on patient characteristics, delays to cardioversion, anticoagulation treatment, acute (<30 days) complications, and regimen changes within one year were evaluated.Results Nine hundred patients (59.2% men; mean age, 68.0 +/- 10.0) underwent 992 ECVs, of which 596 (60.0%) were performed using NOACs and 396 (40.0%) using warfarin. The mean CHA(2)DS(2)-VASc score was 2.5 (+/- 1.6). In patients without previous anticoagulation treatment, NOACs were associated with a shorter mean time to cardioversion than warfarin (51 versus. 68 days, respectively; p < .001). Six thromboembolic events (0.6%) occurred: 4 (0.7%) in NOAC-treated patients and 2 (0.5%) in warfarin-treated patients. Clinically relevant bleeding events occurred in seven patients (1.8%) receiving warfarin and three patients (0.5%) receiving NOACs. Anticoagulation treatment was altered for 99 patients (11.0%) during the study period, with the majority (88.2%) of changes from warfarin to NOACs.Conclusions In this real-life study, the rates of thromboembolic and bleeding complications were low in AF patients undergoing ECV. Patients receiving NOAC therapy had a shorter time to cardioversion and continued their anticoagulation therapy more often than patients on warfarin.
Downloadable publication This is an electronic reprint of the original article. |  |
